NDLI: Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion

Content Provider	PubMed Central
Author	Toomer, Kevin H. Chen, Zhibin
Copyright Year	2014
Abstract	Cancer immunotherapy through manipulation of the immune system holds great potential for the treatment of human cancers. However, recent trials targeting the negative immune regulators cytotoxic T-lymphocyte antigen 4, programed death 1 (PD-1), and PD-1 receptor ligand (PD-L1) demonstrated that clinically significant antitumor responses were often associated with the induction of autoimmune toxicity. This finding suggests that the same immune mechanisms that elicit autoimmunity may also contribute to the destruction of tumors. Given the fact that the immunological identity of tumors might be largely an immunoprivileged self, autoimmunity may not represent a wholly undesirable outcome in the context of cancer immunotherapy. Rather, targeted killing of cancer cells and autoimmune damage to healthy tissues may be intricately linked through molecular mechanisms, in particular inflammatory cytokine signaling. On the other hand, since chronic inflammation is a well-recognized condition that promotes tumor development, it appears that autoimmunity can be a “double agent” in mediating either pro-tumor or antitumor effects. This review surveys the tumor-promoting and tumoricidal activities of several prominent cytokines: IFN-γ, TNF-α, TGF-β, IL-17, IL-23, IL-4, and IL-13, produced by three major subsets of T helper cells that interact with innate immune cells. Many of these cytokines exert divergent and seemingly contradictory effects on cancer development in different human and animal models, suggesting a high degree of context dependence in their functions. We hypothesize that these inflammatory cytokines could mediate a feedback loop of autoimmunity, antitumor immunity, and tumorigenesis. Understanding the diverse and paradoxical roles of cytokines from autoimmune responses in the setting of cancer will advance the long-term goal of improving cancer immunotherapy, while minimizing the hazards of immune-mediated tissue damage and the possibility of de novo tumorigenesis, through proper monitoring and preventive measures.
Related Links	http://dx.doi.org/10.3389/fimmu.2014.00116
Starting Page	116
File Format	PDF
ISSN	16643224
e-ISSN	16643224
Journal	Frontiers in Immunology
Volume Number	5
Language	English
Publisher	Frontiers Media S.A.
Publisher Date	2014-03-01
Access Restriction	Open
Rights Holder	Frontiers Media S.A.
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Autoimmunity as a double agent in tumor killing and cancer promotion

Tumor-killing DCs

Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy

Tumor Immunotherapy: Lessons from Autoimmunity

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

4-Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer

RESISTANCE TO A TUMOR-PRODUCING AGENT AS DISTINCT FROM RESISTANCE TO THE IMPLANTED TUMOR CELLS

Development of an Fn14 agonistic antibody as an anti-tumor agent

Elevated Double Negative T Cells in Pediatric Autoimmunity

Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion

Similar Documents

Autoimmunity as a double agent in tumor killing and cancer promotion

Tumor-killing DCs

Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy

Tumor Immunotherapy: Lessons from Autoimmunity

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

4-Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer

RESISTANCE TO A TUMOR-PRODUCING AGENT AS DISTINCT FROM RESISTANCE TO THE IMPLANTED TUMOR CELLS

Development of an Fn14 agonistic antibody as an anti-tumor agent

Elevated Double Negative T Cells in Pediatric Autoimmunity

Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion